Nods for Atezolizumab and Nivolumab from FDA.
ثبت نشده
چکیده
The FDA has conditionally approved atezolizumab, the first PD-L1 inhibitor, for metastatic urothelial carcinoma, along with a companion diagnostic, the Ventana PD-L1 (SP142) assay. The agency has also expanded nivolumab's indications to include classical Hodgkin lymphoma, making this PD-1 inhibitor the first to be approved for a hematologic malignancy.
منابع مشابه
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
New therapies targeting the programmed death receptor-1 (PD-1) are changing the outcomes of patients with advanced cancers, with randomized trials reporting improvements in overall survival (OS) compared with standard treatment [1–6]. However, there is debate about whether patients should be selected for treatment with these agents based on expression of the PD-1 ligand, PD-L1. The US Food and ...
متن کاملPD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients
Until recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limited improvement compared to best supportive care in second line treatment. In addition, gemcitabine/ cisplatin has been established as an alternative to metho...
متن کاملPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune cells and PD-L1 on cancer cells have been used to successfully treat non-small cell lung cancer (NSCLC), including some durable responses lasting years. Two ...
متن کاملBiomarkers for immunotherapy in bladder cancer: a moving target
Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting the programmed cell death protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis. Notably, the anti-PD-1...
متن کاملNew PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. While PD-1 inhibitors nivolumab and pembrolizumab have been approved for non-small cell lung cancer (NSCLC), this review focuses on atezoliz...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Cancer discovery
دوره 6 8 شماره
صفحات -
تاریخ انتشار 2016